(Q30932202)

27 June 2017

1 reference

title

Cardiovascular tolerability and safety of triptans: a review of clinical data (English)

1 reference

27 June 2017

1 reference

Stephen D. Silberstein

series ordinal

4

object named as

Stephen Silberstein

1 reference

27 June 2017

1

David W Dodick

1 reference

27 June 2017

Vincent T Martin

2

1 reference

PubMed ID

15149490

27 June 2017

Timothy Smith

series ordinal

3

1 reference

27 June 2017

1 May 2004

1 reference

27 June 2017

1 reference

27 June 2017

44 Suppl 1

1 reference

27 June 2017

S20-30

1 reference

Migraine diagnosis and treatment: results from the American Migraine Study II.

27 June 2017

1 reference

https://api.crossref.org/works/10.1111%2FJ.1526-4610.2004.04105.X

Cardiovascular safety of 5HT1B/1D agonists--is there a cause for concern?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1526-4610.2004.04105.X

Eletriptan in acute migraine: a double-blind, placebo-controlled comparison to sumatriptan. Eletriptan Steering Committee.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1526-4610.2004.04105.X

Efficacy, safety and tolerability of oral eletriptan in the acute treatment of migraine: results of a phase III, multicentre, placebo-controlled study across three attacks

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1526-4610.2004.04105.X

Rizatriptan vs sumatriptan in the acute treatment of migraine. A placebo-controlled, dose-ranging study. Dutch/US Rizatriptan Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1526-4610.2004.04105.X

Oral rizatriptan versus oral sumatriptan: a direct comparative study in the acute treatment of migraine. Rizatriptan 030 Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1526-4610.2004.04105.X

Rizatriptan (MAXALT) for the acute treatment of migraine and migraine recurrence. A placebo-controlled, outpatient study. Rizatriptan 022 Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1526-4610.2004.04105.X

Oral almotriptan in the treatment of migraine: safety and tolerability

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1526-4610.2004.04105.X

Naratriptan is effective and well tolerated in the acute treatment of migraine. Results of a double-blind, placebo-controlled, crossover study. The Naratriptan S2WA3003 Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1526-4610.2004.04105.X

Naratriptan is effective and well tolerated in the acute treatment of migraine. Results of a double-blind, placebo-controlled, parallel-group study. Naratriptan S2WA3001 Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1526-4610.2004.04105.X

Efficacy and safety of sumatriptan tablets (25 mg, 50 mg, and 100 mg) in the acute treatment of migraine: defining the optimum doses of oral sumatriptan

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1526-4610.2004.04105.X

Tolerability and efficacy of almotriptan in the long-term treatment of migraine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1526-4610.2004.04105.X

Prospective large-scale study of the tolerability of subcutaneous sumatriptan injection for acute treatment of migraine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1526-4610.2004.04105.X

Efficacy and tolerability of rizatriptan 10 mg in migraine: experience with 70 527 patient episodes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1526-4610.2004.04105.X

Tolerability and efficacy of naratriptan tablets in the acute treatment of migraine attacks for 1 year. Naratriptan Long-Term Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1526-4610.2004.04105.X

Vasospasm-induced myocardial infarction with sumatriptan

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1526-4610.2004.04105.X

Transmural myocardial infarction with sumatriptan

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1526-4610.2004.04105.X

Cardiac arrest following use of sumatriptan

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1526-4610.2004.04105.X

Fatal cardiac arrhythmia after oral sumatriptan

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1526-4610.2004.04105.X

Cardiac arrest and myocardial infarction immediately after sumatriptan injection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1526-4610.2004.04105.X

Vascular effects of 5-HT1B/1D-receptor agonists in patients with migraine headaches.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1526-4610.2004.04105.X

Hemodynamic and electrocardiographic effects of almotriptan in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1526-4610.2004.04105.X

Effect of subcutaneous sumatriptan, a selective 5HT1 agonist, on the systemic, pulmonary, and coronary circulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1526-4610.2004.04105.X

A study of the effects of sumatriptan on myocardial perfusion in healthy female migraineurs using 13NH3 positron emission tomography

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1526-4610.2004.04105.X

State of the art in stress testing and ischaemia monitoring

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1526-4610.2004.04105.X

Migraine and angina pectoris by coronary artery spasm

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1526-4610.2004.04105.X

Is chest pain after sumatriptan oesophageal in origin?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1526-4610.2004.04105.X

Effects of the anti-migraine drug sumatriptan on muscle energy metabolism: relationship to side-effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1526-4610.2004.04105.X

Evidence for 5-HT1-like receptor-mediated vasoconstriction in human pulmonary artery

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1526-4610.2004.04105.X

10.1111/J.1526-4610.2004.04105.X

21 January 2018

Identifiers

DOI

1 reference

27 June 2017

1 reference

PubMed ID

15149490